

SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

Phenoxymethylpenicillin 250mg/5ml Powder for Oral Solution

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 5ml of Oral Solution contains 250mg of Phenoxymethylpenicillin as Phenoxymethylpenicillin Potassium.

Excipient(s) with known effect:

For a full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Powder for oral solution

White to off white granular powder, free from agglomerates or caking.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Phenoxymethylpenicillin and phenoxymethylpenicillin potassium are indicated in the treatment of mild to moderately severe infections associated with micro-organisms whose susceptibility to penicillin is within the range of serum levels attained with the dosage form.

Phenoxymethylpenicillin is indicated for the treatment of the following infections (see section 4.4 and 5.1)

Streptococcal infections:

Pharyngitis

Scarlet fever

Skin and soft tissue infections (e.g. erysipelas) Pneumococcal infections:

Pneumonia

Otitis media

Vincent's gingivitis and pharyngitis

Phenoxymethylpenicillin is also indicated for (see section 5.1):

Prophylaxis of rheumatic fever and/or chorea

Prophylaxis of pneumococcal infection (e.g. in asplenia and inpatients with sickle cell disease)

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

4.2 Posology and method of administration

Posology

For oral administration only.

The dosage and frequency of Phenoxymethylpenicillin depends on the severity and localisation of the infection and expected pathogens.

Phenoxymethylpenicillin Solution should be taken at least 30 minutes before or 2 hours after food, as ingestion of Phenoxymethylpenicillin with meals slightly reduces the absorption of the drug.

Phenoxymethylpenicillin 250mg is approximately equivalent to 400,000 units.

The usual dosage recommendations are as follows:

Adults (including the elderly) and children over 12 years:	250mg - 500mg every six hours
Children:	
Infants (up to 1 year)	62.5mg every six hours
1-5 years	125mg every six hours
6-12 years	250mg every six hours

Prophylactic Use

Prophylaxis of rheumatic fever/chorea: 250mg twice daily on a continuing basis

Prophylaxis of pneumococcal infection (e.g. in asplenia and in sickle cell disease):

Adults and children over 12 years: 500mg every 12 hours
Children 6-12 years: 250mg every 12 hours

Children below 5 years: 125mg every 12 hours.

Elderly

The dosage is as for adults. The dosage should be reduced if renal function is markedly impaired.

Renal impairment

The dosage should be reduced if renal function is markedly impaired.

Hepatic impairment

Dosage adjustment may be necessary in patients with impaired liver function when they also have renal failure. In this situation the liver may be a major excretion route.

Method of Administration

For instructions on reconstitution of the medicinal product before administration, see section 6.6.

4.3 Contraindications

Phenoxymethylpenicillin is contraindicated in patients known to be hypersensitive to Penicillin or to any of the excipients listed in section 6.1 and should be used with caution in patients with known histories of allergy.

4.4 Special warnings and precautions for use

Penicillin should be used with caution in individuals with histories of significant allergies and/or asthma. All degrees of hypersensitivity, including fatal anaphylaxis, have been observed with oral penicillin. These reactions are more likely to occur in individuals with a history of sensitivity to penicillins, cephalosporins and other allergens. Enquiries should be made for such a history before therapy is begun. If any allergic reaction occurs, the drug should be discontinued and the patient treated with the usual agents (e.g. adrenaline and other pressor amines, antihistamines and corticosteroids).

Oral therapy should not be relied upon for patients with severe illness, or with nausea, vomiting, gastric dilation, achalasia or intestinal hypermotility.

Occasionally patients do not absorb therapeutic amounts of orally administered penicillin.

Administer with caution in the presence of markedly impaired renal function, as safe dosage may be lower than the usually recommended doses.

Streptococcal infections should be treated for a minimum of 10 days, and post therapy cultures should be performed to confirm the eradication of the organisms.

Prolonged use of antibiotics may promote the over growth of non-susceptible organisms, including fungi. If super infection occurs, appropriate measures should be taken.

Sucrose:

This product contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction

Aminoglycosides: Neomycin is reported to reduce the absorption of phenoxymethylpenicillin.

Anticoagulants: Penicillins may interfere with anticoagulant control.

Bacteriostatic antibiotics: Certain bacteriostatic antibiotics such as Chloramphenicol, Erythromycin and Tetracyclines have been reported to antagonise the bactericidal activity of penicillins and concomitant use is not recommended.

Guar gum: Reduced absorption of phenoxymethylpenicillin

Methotrexate: Use of Phenoxymethylpenicillin while taking methotrexate can cause reduced excretion of methotrexate thereby increasing the risk of toxicity.

Probenecid: Reduced excretion of phenoxymethylpenicillin by competing with it for renal tubular secretion.

Sulfinpyrazone: Excretion of penicillins reduced by sulfinpyrazone.

Typhoid vaccine (oral): Penicillins may inactivate oral typhoid vaccine if ingested concomitantly.

4.6 Fertility, pregnancy and lactation

Pregnancy:

There are no or a limited amount of data from the use of Phenoxymethylpenicillin in pregnant women. As a precautionary measure, it is preferable to avoid the use of Phenoxymethylpenicillin during pregnancy.

Breast-feeding:

Phenoxymethylpenicillin metabolites are excreted in human milk to such an extent that effects on breastfed newborns are likely.

4.7 Effects on ability to drive and use machines

None known

4.8 Undesirable effects

The most common reactions to oral penicillin are gastrointestinal effects and hypersensitivity reactions. Although hypersensitivity reactions have been

reported much less frequently after oral than after parenteral therapy, it should be remembered that all forms of hypersensitivity, including fatal anaphylaxis have been observed with oral penicillin.

<p>The following convention has been utilised for the classification of undesirable effects:-</p> <p>Very common (>1/10)</p> <p>Common (>1/100, <1/10)</p> <p>Uncommon (>1/1000, <1/100)</p> <p>Rare (>1/10,000, <1/1000)</p> <p>Very rare (<1/10,000)</p> <p>Not known (cannot be estimated from the available data).</p>		
Infections and infestations	Not known	Pseudomembranous colitis
Blood and lymphatic disorders	Very rare	Changes in blood counts, including, thrombocytopenia, neutropenia, leucopenia, eosinophilia and haemolytic anaemia.
	Not known	Coagulation disorders
		(including prolongation of bleeding time and defective platelet function)
Gastrointestinal disorders	Common	Nausea, vomiting, abdominal pain, diarrhoea
	Not known	Sore mouth and black hairy tongue (discolouration of tongue)
Hepatobiliary disorders	Very rare	Hepatitis and cholestatic jaundice
Immune disorders	Common	Allergic reactions (typically manifest as skin reactions (See Skin and subcutaneous disorders)).
	Rare	Severe allergic reactions causing angioedema, laryngeal oedema and anaphylaxis
	Unknown	Serum sickness-like reactions characterised by fever, chills, arthralgia and oedema

Nervous system disorders	Unknown	Central nervous system toxicity including convulsions (especially with high doses or in severe renal impairment); paraesthesia may occur with prolonged use, Neuropathy (usually associated with high doses of parenteral penicillin)
Renal and urinary disorders	Very rare	Interstitial nephritis
	Uncommon	Nephropathy (usually associated with high doses of parenteral penicillin)
Skin and subcutaneous disorders	Common	Urticarial, erythematous or morbilliform rash and pruritus
	Rare	Exfoliative dermatitis

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the yellow card scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Symptoms: A large oral overdose of penicillin may cause nausea, vomiting, stomach pain, diarrhoea, and rarely, major motor seizures. If other symptoms are present, consider the possibility of an allergic reaction. Hyperkalaemia may result from overdosage, particularly for patients with renal insufficiency.

Management: No specific antidote is known. Symptomatic and supportive therapy is recommended. Activated charcoal with a cathartic, such as sorbitol may hasten drug elimination. Penicillin may be removed by haemodialysis.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

General properties

ATC classification Pharmacotherapeutic Group: Beta lactamase sensitive natural penicillins ATC Code: J01C E02.

Mechanism of Action

Phenoxymethylpenicillin acts through interference with the final stage of synthesis of the bacterial cell wall. The action depends on its ability to bind certain membranebound proteins, (penicillin-binding proteins or PBPs) that are located beneath the cell wall. These proteins are involved in maintaining cell wall structure, in cell wall synthesis and in cell division, and appear to possess transpeptidase and carboxypeptidase activity.

PK/PD relationship

The time above the minimum inhibitory concentration (T>MIC) is considered to be the major determinant of efficacy for phenoxymethylpenicillin.

Mechanism(s) of Resistance:

Phenoxymethylpenicillin is inhibited by penicillinase and other betalactamases that are produced by certain micro-organisms. The incidence of beta-lactamase producing organisms is increasing.

Mechanisms of resistance

The two main mechanisms of resistance to phenoxymethylpenicillin are:

- Inactivation by bacterial penicillinases and other beta-lactamases
- Alteration of PBPs, which reduce the affinity of the antibacterial agent for the target.

Impermeability of bacteria or efflux pump mechanisms may cause or contribute to bacterial resistance.

EUCAST clinical MIC breakpoints to separate susceptible (S) pathogens from resistant (R) pathogens (version 1.0 22.11.210) are:

The susceptibility of streptococci Groups A, C and G and *S. pneumoniae* to phenoxymethylpenicillin is inferred from the susceptibility to benzylpenicillin.

EUCAST Species-related breakpoints (Susceptible≤/Resistant>) Units:	
mg/L	
Staphylococcus	≤0.12/>0.12
Streptococcus A, C, G	≤0.25/>0.25
<i>S. pneumoniae</i>	≤ 0.06/>2

Staphylococci: Most staphylococci are penicillinase-producers. Penicillinase producing strains are resistant. The benzylpenicillin breakpoint (shown) will mostly, but not unequivocally, separate beta-lactamase producers from nonproducers.

Streptococcus pneumoniae: For phenoxymethylpenicillin, report *S. pneumoniae* with benzylpenicillin MICs above 0.06 mg/L resistant.

The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. Expert advice should be sought as necessary when the local prevalence of resistance is such that the utility of the agent in at least some types of infection is questionable.

Commonly susceptible species
Streptococcus A, B, C, G
Species for which acquired resistance may be a problem
<i>Staphylococcus aureus</i>
<i>Streptococcus pneumonia</i>
<i>Staphylococcus epidermidis</i>

5.2 Pharmacokinetic properties

Absorption

Rapidly but incompletely absorbed after oral administration (about 60% of an oral dose is absorbed). Calcium and potassium salts are better absorbed than the free acid. Absorption appears to be reduced in patients with coeliac disease. Absorption appears to be more rapid in fasting than non-fasting subjects.

Blood concentration: after an oral dose of 125mg, peak serum concentrations of 200 to 700ng/ml are attained in 2 hours. After an oral dose of 500mg, peak serum concentrations reach 3 to 5micrograms/ml in 30 to 60 minutes.

Half-life: Biological half-life is about 30 minutes, increased to about 4 hours in severe renal impairment.

Distribution

Widely distributed throughout the body and enters pleural and ascitic fluids and also in cerebrospinal fluid when the meninges are inflamed; Phenoxymethylpenicillin crosses the placenta and is secreted in the milk; (protein binding 50 to 80% bound plasma proteins).

Biotransformation: It is metabolised in the liver; several metabolites have been identified, including penicilloic acid.

Elimination: Unchanged drug and metabolites are excreted rapidly in the urine. (20% to 35% of an oral dose is excreted in the urine in 24 hours).

5.3 Preclinical safety data

There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of this SPC.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sucrose

Saccharin Sodium (E954)

Flavour Orange powder (0473075)

Flavour Refreshing powder (0479539) (Menthol)

6.2 Incompatibilities

None known

6.3 Shelf life

24 Months Unopened, 7 days after reconstitution

6.4 Special precautions for storage

Dry powder: Store below 25°C, Store in the original package.

Reconstituted solution: Store up to 7 days at 2°C – 8°C in a refrigerator.

6.5 Nature and contents of container

Translucent HDPE round bottle with White Round polypropylene CR Cap liner containing 100 ml of oral Solution on reconstitution.

6.6 Special precautions for disposal

Phenoxymethylpenicillin is Slight opaque solution with orange odour. Add 65mls of potable water for the 250mg/5ml strength of product and shake gently until all powder is dissolved.

No special requirements for disposal.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7 MARKETING AUTHORISATION HOLDER

Flamingo Pharma UK Ltd.
1st floor, Kirkland House,
11-15 Peterborough Road,
Harrow, Middlesex,
HA12AX, United Kingdom.

8 MARKETING AUTHORISATION NUMBER(S)

PL 43461/0028

**9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION**

27/09/2019

10 DATE OF REVISION OF THE TEXT

21/10/2020